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SUMMARY 
The association of sodium valproate with cognitive functions was studied in 29 patients with complex absence 
seizures. Seventeen patients were on monotherapy and twelve on polypharmacy with sodium valproate. Cognitive 
functions assessed were attention, speech, visuo-speciat perception, memory and intelligence. Behavioral distur-
bances were also assessed. Two assessments were made six months apart; in the first assessment, attention and 
speech were adequate, while memory, visuo-spatial perception, and behavioral functioning were impaired. 
Intelligence was lower in the polypharmacy group, while other functions were similar. In the second assessment, 
intelligence and visual memory improved in the monotherapy group, while no changes were present in the 
polypharmacy group. 
INTRODUCTION 
Antiepleptic drug therapy is found to affect cognitive 
functioning (Vining, 1987). In normal volunteers, cogni-
tive deficits in memory and information processing tasks 
were recorded in association with phenytoin, car-
bamazepine, sodium valproate, clobazam and 
clonazepam, fewer deficits being associated with sodium 
valproate, carbamazepine and clobazam (Trimble, 1987). 
Sodium valproate has been found to improve intellect, as 
patients become more alert and co-operative (Volzke & 
Doose, 1973). Better attention and school performance has 
been reported in children on sodium valproate (Jeavons & 
Clark, 1974), while reaction time has been reported as 
decreased inchildrcn and adolescents on sodium valproate 
(Harding et al, 1978). Valproate is associated with better 
behavioral and neuropsychological functioning compared 
with phenobarbital (Vining et al, 1987); in addition, in 
normal volunteers, it is associated with improved alertness 
(Belts et al, 1982). Contrary to these observations, there 
are a few reports that sodium valproate has a few adverse 
effects on cognitive functions. In normal volunteers, 
sodium valproate was associated with slowing down of 
mental processing speed which reached significance only 
when the demands of the task increased (Trimble, 1987). 
Addition of sodium valproate to drug resistant epileptics 
resulted in increased reaction time as well as increased 
time on tasks which required attention and had competing 
responses (Sommerbeck et al, 1977). As a monotherapy 
in high doses, it led to impairment of memory and auditory 
detection (Trimble & Thompson, 1983). 
In view of the contradictory findings reported above, 
the present study was undertaken to evaluate the effect of 
sodium valproate on cognitive functioning in epileptic 
patients. It isincreasingly felt that, in managing any patient 
with epilepsy, reduction in cognitive dysfunction and 
seizure frequency should be viewed together, without 
sacrificing one for another (Vining, 1987). In the present 
study, the association of sodium valproate with cognitive 
functioning was investigated by comparing two groups of 
patients. In the first group sodium valproate was used 
singly (monotherapy), whereas in the second group, it was 
used in conjunction with other antiepileptic drugs [AED] 
such as phenobarbitone, phenytoin, carbamazepine or 
benzodiazepines. By comparing its effect in isolation 
(monotherapy group) with its effect in interaction with 
other AEDs (polypharmacy group), the effect of sodium 
valproate on cognitive functioning in epileptics could be 
studied. 
MATERIALS AND METHODS 
Subjects 
Twenty-nine patients, with complex absence as the 
predominant seizure type who were on monotherapy with 
sodium valproate (n=17) or on polypharmacy (i.e., 
phenobarbitone, phenytoin, carbamazepine & ben-
zodiazepines) inclusive of sodium valproate (N=12) were 
included in the study. This sample was drawn from the 
Neurology out-patient service of the National Institute of 
Mental Health and Neurosciences (NIMHANS) between 
1984-86 and formed the sample for a clinical drug trial on 
sodium valproate. Six patients in the monotherapy group 
and five patients in the polypharmacy group were males. 
Sample characteristics are shown in Table I. 
Assessment Of Cognitive Functions 
Two assessments were conducted, the initial after the 
commencement of sodium valproate and the second, six 
months later. The period of sodium valproate use before 
the first assessment varied from 1 to 23 months with a 
mean of 16 months in the monotherapy group. In the 
polypharmacy group, it ranged from 3-22 months, the 
mean being 17 months (Table I). The second assessment 
enabled evaluation of cognitive and behavioral functions 
associated with continued use of sodium valproate either 
as monotherapy or as a component of polypharmacy. 
Attention was assessed using the components of spon-
taneous arousal, distractibility, fatiguability and per-
severation. Speech was assessed in terms of the adequacy 
of expressive and receptive speech. Attention and speech 
were rated on a 5 point scale with 5 indicating adequate 
functioning. Visuo-spatial perception was assessed using 
the complex figure test, an adaptation of Rey-Osterich 
figure (Mukundan et al, 1979). Copying of this figure was 
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TABLE I: SAMPLE CHARACTERISTICS 
Clinical Variable 
Age(Yrs) 
Education (yrs of) 
schooling) 
Age of onset (Yrs) 
Duration of seizures (yrs) 
Seizure Frequency 
Before Valproate use 
Duration (mths) 
of Valproate treatment 
Duration of seizure control 
with Valproate (mths) 
Co-existent seizure type 
Tonic-clonic 
EEG 
Serum Level 
of Valproate 
Mean 
11.6 
(4.6) 
6.0 
P.4) 
16.0 
(6.4) 
iae 
(5.0) 
<50ug/ml 
50-100ug/ml 
>100ug/ml 
IIONOTHERAPYn=17 
Range 
5-22 
1-12 
2-3/day 
50-100/day 
1-23 
5-20 
Category 
s12 
>12 
<10 
a 10 
s10 
>10 
s3 
>3 
s 10/day 
i >10/day 
s18 
>18 
s12 
>12 
Normal 
Abnormal 
N 
11 
6 
14 
3 
13 
4 
9 
8 
4 
13 
7 
5 
7 
10 
3 
7 
9 
4 
9 
2 
Mean 
16.0 
(3.1) 
7.3 
(3.0) 
17.0 
(5.6) 
8.8 
(5.3) 
POLYPHARMACY n=12 
Range 
12-22 
0-10 
8-15/day 
numerous 
3-22 
1-18 
Category 
s12 
>12 
<10 
2 10 
<10 
>10 
s3 
>3 
s 10/day 
>10/day 
s18 
>18 
s12 
>12 
Normal 
Abnormal 
N 
2 
10 
8 
4 
7 
5 
3 
9 
0 
12 
10 
7 
9 
3 
12 
5 
7 
6 
5 
1 
Significance 
level 
p<0.001 
NS 
NS 
NS 
NS 
NS 
NS 
p<0.001 
NS 
NS 
NB: In the monotherapy group, serum level was ascertained in 15 patients only. Significance levels refer to the X' test between the categories of 
patients in the two groups for each variable. 
scored for its accuracy, the maximum score being 20. 
Immediate memory was assessed with digit forward and 
backward test, a subtest of the Binet Kamath test (Kamath, 
1967). The number of digits recalled in either condition 
formed the score. Visual memory was tested using the 
complex figure test, wherein three repeated exposure 
recall sequences were followed by a delayed recall after 
10 minutes. Mean accuracy of recall over the four trails 
formed the score, with the maximum score being 20. 
Verbal memory was tested by auditory presentation fol-
lowed by recall of two story passages. For each passage 
three repeated exposure recall sequences were followed 
by adelayed recall after lOminutes. Mean number of facts 
correctly recalled from both passages formed the score, the 
maximum score being 21. Intelligence was measured 
using the Binet Kamath test (Kamath, 1976). 
Behavioral disturbances were rated by interviewing 
parents of patients using O'Connor's abbreviated rating 
scale (Goyette et al, 1978) and Achenbach rating scale for 
children below 16 years (Achenbach & Edelbrock, 1983). 
Adultj>atients were assessed using Bell's adjustment in-
ventory (Bell, 1938). Behavioral disturbances were rated 
on a five point scale with 5 indicating adequate function-
ing. 
RESULTS 
The two groups were comparable with respect to most 
of the clinical variables known to affect cognitive 
functioning in epileptics (Table I). These include age of 
onset, seizure duration, seizure frequency, presence of 
EEG abnormalities, seizure free period prior to 
psychological assessment and serum level of the AED 
(Dodrill & Wilkus, 1978; Thompson & Trimble, 1982). 
Patients in the polypharmacy group were significantly 
older, the difference being four years. Tonic-clonic 
seizures as a co-existent seizure type was also present in a 
significantly larger number of patients in the polyphar-
macy group. 
The performance of the monotherapy and polyphar-
macy groups in the first assessment are depicted in Table 
II. T test for uncorrelated means revealed that the two 
groups differed significantly in intelligence; the polyphar-
macy group being 17 I.Q. points below the monotherapy 
group. The two groups performed similarly on all other 
functions. A clinical profile of the mean scores reveal that 
in both groups attention and speech were adequate. 
Visuospatial perception was minimally impaired, i.e. 14-
15/21 (maximum score). Immediate memory was 
moderately impaired. Visual and verbal memory were 
moderately impaired i.e., 8-9/20 (maximum score) and 
10-12/21 (maximum score), respectively. Intelligence was 
in the normal range in the monotherapy group, but in the 
polypharmacy group, the mean I.Q. was below the normal 
range. Behavior functioning was minimally impaired in 
both groups, i.e. a mean rating near 4. Performance on the 
second assessment was compared with that on the first 
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Table II Mean and Standard deviation of tha acoraa on thai dif-
ferent taata for Monotherapy and Polypharmacy group* In tha Aral 
aaaaaamant. 
FUNCTION MONOTHERAPY 
Attention 
Speech 
Visuo-spatial 
perception 
Immediate Memory 
Digit Forward 
Immediate Memory: 
Digit Backward 
Visual Memory 
Verbal Memory 
Intelligence 
Behavior 
4.8 
(1.0) 
5.0 
(0) 
14.2 
(5.6) 
3.5 
(1.8) 
1.7 
(1.8) 
9.0 
(4.0) 
120 
(6.1) 
98.0 
(15.6) 
4.2 
(1.1) 
POLYPHARMACY 
4.7 
(-9) 
4.9 
(3) 
15.4 
(4.4) 
2.8 
(1.4) 
2.1 
(1.7) 
8.0 
(3.2) 
10.2 
(5.7) 
81.2 
(224) 
3.6 
(1.3) 
t 
-.04 
1.29 
-.63 
1.1 
-.5 
-.9 
0.7 
24* 
1.2 
NB: Cell entries under the two groups are mean scores. 
Standard deviation is given in brackets. 
*P<0.05 
using the t test for dependent means. Table III shows that 
performance did not differ between the first and second 
assessments on any of the functions in the polypharmacy 
group. In the monotherapy group, visual memory and 
intelligence had improved significantly in the second as-
sessment, the gain in visual memory being small, though 
significant. The gain in intelligence is nearly 9 points and 
is substantial and significant. Performance on the other 
functions had not changed in the second assessment. 
DISCUSSION 
Sodium valproate administered as monotherapy in 
complex absence is associated with normal intellectual 
functioning. Administration in conjunction with other 
AEDs is associated with a below normal level of intellec-
tual functioning. This poor intellectual functioning may be 
not entirely due to polypharmacy alone. The other sig-
nificant clinical variables on which the two groupsdiffered 
were age of the patient and co-existent type of seizures. 
The polypharmacy group was older, i.e. mean age of 16 
years as compared to 11.6 years in the monotherapy group. 
However, as the I.Q was scored on age appropriate norms, 
the age of the patient is unlikely to have influenced the I.Q. 
scores. The other significant difference was the presence 
of tonic-clonic seizures and the use of multiple anticon-
vulsant drugs in these patients. 
Intellectual performance and other cognitive functions 
in epileptics are known to be affected by age of onset 
(O'Leary et al, 1981), duration of seizures (Lennox & 
Lennox, I960), frequency of attacks (Dikmen & Mat-
Table II Mean and Standard deviation of the acoraa on tha dif-
ferent taata for Monotherapy and Polypharmacy groups In tha I 
and II assessment. 
FUNCTION MONOTHERAPY POLYPHARMACY 
Assesment Assessment 
Attention 
Speech 
Visuo-spatial 
perception 
Imm Memory 
Digit Forward 
Imm Memory 
Digit Backrd 
Visual 
Memory 
Verbal 
Memory 
Intelligence 
Behavior 
1 
4.8 
(10) 
5.0 
(0) 
14.2 
(56) 
3.5 
(18) 
1.7 
(1.8) 
9.0 
(4.0) 
12.0 
(6.1) 
98.0 
(15.6) 
4.2 
(11) 
II 
4.8 
(0.5) 
5.0 
(0) 
14.5 
(5.4) 
3.2 
(1.8) 
2.2 
(2.0) 
11.0 
(3.5) 
13.1 
(3.8) 
107 
(17.5) 
4.3 
(0.9) 
t 
•0.4 
0 
•0.5 
0.9 
•1.3 
•2.6* 
•1.1 
•3,6' 
•0.4 
I 
4.7 
(0.9) 
4.9 
(0.3) 
15.4 
(4.4) 
2.8 
(1.4) 
2.1 
(1.7) 
8.0 
(3.2) 
10.2 
(5.7) 
81.2 
(22.4) 
3.6 
(1.3) 
II 
4.8 
(0.6) 
5.0 
(0) 
16.3 
(5.3) 
3.1 
(1.3) 
1.6 
(1.0) 
7.1 
(2.7) 
9.0 
(4.6) 
78.2 
(18.0) 
3.1 
(1.4) 
t 
-0.3 
•1.0 
-1.2 
-0.9 
0.4 
0.5 
0.3 
•0.4 
0.7 
NB: Cell entries under the two groups are mean scores. 
Standard deviation is given in brackets. 
P<0.05 
thews, 1977) and duration of seizure control (Virmani et 
al, 1973). In the present study, the two groups were com-
parable on all the above parameters (Table I). They were 
also comparable with regard to the presence of EEG 
abnormalities and serum level of sodium valproate. In 
view of this large homogeneity between the two groups, 
the differences in I.Q. may be attributed to the polyphar-
macy such as barbiturate and the presence of tonic-clonic 
seizures as the co-existent type. Further studies on a larger 
sample are required to separate these two influences on 
intelligence. 
It is significant to note that the two groups are com-
parable on all other cognitive functions. In both groups the 
clinical profile indicates adequate attention and speech, 
but impaired visuo-spatial perception, immediate, visual 
and verbal memory. Behavior problems exist to a minimal 
extent in the nature of poor adjustment in the home sphere, 
irritability, stubbornness, moodiness and hyperactivity. 
Improved alertness has been associated with sodium 
valproate (Jeavons& Clark, 1974), which may explain the 
presence of adequate attention at the first assessment. 
Slowing down of mental processing with increased 
task demands associated with sodium valproate (Trimble, 
1987), cannot explain the deficits in visuo-spatial percep-
tion and memory functions present in both groups. As this 
slowing down would have a generalized effect on all 
cognitive functions, normal intellectual performance in 
the monotherapy group cannot be accounted for with thif 
explanation. 
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The second assessment after six months indicated that 
continued use of sodium valproate was not associated with 
any improvement or worsening of cognitive or behavioral 
functions in the polypharmacy group. However, in the 
monotherapy group, it was associated with improvement 
of visual memory and intelligence; it is difficult to attribute 
this improvement to practice effects, as these effects are 
not group or function specific. Further studies with larger 
samples are required toclarify these preliminary observa-
tions regarding the effect of sodium valproate on cognitive 
functions in patients with complex absence seizures. 
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